Nestlé Health Science partners with Enterome to treat food allergies and bowel inflammation
In a newly inked deal with Nestlé Health Science, the French firm partly owned by the Lundbeck Foundation will zoom in on inflammatory bowel disease (IBD) and food allergies, beginning with peanuts.
by christopher due karlsson, translated by daniel pedersen
French Biotech firm Enterome, partly owned by the Lundbeck Foundation, has entered a strategic research and development partnership regarding food allergies and inflammatory bowel disease (IBD) with Nestlé Health Science, according to a company press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
ALK expects to have approved peanut allergy vaccine in 2030
For subscribers
